首页 > 最新文献

Biomedicine Hub最新文献

英文 中文
Video-Assisted Thyroidectomy Using a Surgical Energy Device: Initial Experience in a Japanese Single-Center Cohort. 使用手术能量装置的视频辅助甲状腺切除术:日本单中心队列的初步经验。
Pub Date : 2021-12-10 eCollection Date: 2021-09-01 DOI: 10.1159/000520098
Jun-Ichi Ohkubo, Tetsuro Wakasugi, Shoko Takeuchi, Shoichi Hasegawa, Azusa Takahashi, Hideaki Suzuki

Objective: Video-assisted thyroidectomy (VAT) was approved for coverage under the Japanese public health insurance system in 2016. In our department, we introduced VAT in 2018, and we have since been performing the procedure with the assistance of surgical energy devices. We herein summarize our cases undergoing VAT, including a review of points to consider when introducing the procedure, and characteristics of the surgical energy devices.

Methods: We enrolled 24 patients (14 women and 10 men; age: 24-83 years; mean: 59.0 years) with thyroid/parathyroid tumors who underwent VAT between January 2018 and March 2021 at our department. The medical records of the patients were reviewed, and demographic data, clinical characteristics, histological type, treatment outcomes, and complications were analyzed.

Results: The surgical energy devices used were LigaSure® in the first 4 cases, Acrosurg®. Scissors S17 in the next 13 cases, and Acrosurg®. Revo S15 in the latest 7 cases. The operation time (range: 72-250 min; mean: 147 min), intraoperative blood loss (range: 5-370 mL; mean: 33 mL), indwelling time of wound drain (range: 2-6 days; mean: 3.5 days), and hospitalization period (range: 3-8 days; mean: 5.5 days) were within acceptable ranges. In this study, it is suggested that Acrosurg®. Revo S15 can shorten the indwelling time and the hospitalization period. There were no serious complications, but 1 patient developed transient vocal cord paralysis, which improved 3 months after surgery. It was suggested that the microwave energy devices, Acrosurg®. Scissors S17 and Acrosurg®. Revo S15, may be more effective with respect to sealing/hemostasis/coagulation capacity and controllability than the high-frequency electrosurgical device, LigaSure®.

Conclusion: Based on this initial experience, VAT using surgical energy devices appeared to be a safe, effective, and minimally invasive procedure for the treatment of thyroid/parathyroid tumors. Further studies confirming these early findings are needed.

目的:2016年,视频辅助甲状腺切除术(VAT)被批准纳入日本公共医疗保险体系。在我们部门,我们于2018年引入了增值税,此后我们一直在手术能量装置的帮助下进行手术。我们在此总结我们的病例进行增值,包括要点审查时要考虑的程序,并介绍手术能量装置的特点。方法:我们招募了24例患者(女性14例,男性10例;年龄:24-83岁;平均年龄:59.0岁),于2018年1月至2021年3月在我科接受VAT手术。回顾了患者的医疗记录,并分析了人口统计学资料、临床特征、组织学类型、治疗结果和并发症。结果:前4例采用LigaSure®手术能量装置,Acrosurg®手术能量装置。剪刀S17在接下来的13例,和Acrosurg®。Revo S15最新的7起案件。操作时间(范围:72-250分钟;平均:147 min),术中出血量(范围:5-370 mL;平均:33 mL),伤口引流液留置时间(范围:2-6天;平均:3.5天),住院时间(范围:3-8天;平均:5.5天)在可接受范围内。在本研究中,建议使用Acrosurg®。Revo S15可缩短留置时间和住院时间。无严重并发症,但有1例出现一过性声带麻痹,术后3个月好转。建议采用微波能装置Acrosurg®。剪刀S17和Acrosurg®。Revo S15在密封/止血/凝血能力和可控性方面可能比高频电手术设备LigaSure®更有效。结论:基于这一初步经验,使用手术能量装置的VAT似乎是一种安全、有效和微创的治疗甲状腺/甲状旁腺肿瘤的方法。需要进一步的研究来证实这些早期发现。
{"title":"Video-Assisted Thyroidectomy Using a Surgical Energy Device: Initial Experience in a Japanese Single-Center Cohort.","authors":"Jun-Ichi Ohkubo,&nbsp;Tetsuro Wakasugi,&nbsp;Shoko Takeuchi,&nbsp;Shoichi Hasegawa,&nbsp;Azusa Takahashi,&nbsp;Hideaki Suzuki","doi":"10.1159/000520098","DOIUrl":"https://doi.org/10.1159/000520098","url":null,"abstract":"<p><strong>Objective: </strong>Video-assisted thyroidectomy (VAT) was approved for coverage under the Japanese public health insurance system in 2016. In our department, we introduced VAT in 2018, and we have since been performing the procedure with the assistance of surgical energy devices. We herein summarize our cases undergoing VAT, including a review of points to consider when introducing the procedure, and characteristics of the surgical energy devices.</p><p><strong>Methods: </strong>We enrolled 24 patients (14 women and 10 men; age: 24-83 years; mean: 59.0 years) with thyroid/parathyroid tumors who underwent VAT between January 2018 and March 2021 at our department. The medical records of the patients were reviewed, and demographic data, clinical characteristics, histological type, treatment outcomes, and complications were analyzed.</p><p><strong>Results: </strong>The surgical energy devices used were LigaSure® in the first 4 cases, Acrosurg®. Scissors S17 in the next 13 cases, and Acrosurg®. Revo S15 in the latest 7 cases. The operation time (range: 72-250 min; mean: 147 min), intraoperative blood loss (range: 5-370 mL; mean: 33 mL), indwelling time of wound drain (range: 2-6 days; mean: 3.5 days), and hospitalization period (range: 3-8 days; mean: 5.5 days) were within acceptable ranges. In this study, it is suggested that Acrosurg®. Revo S15 can shorten the indwelling time and the hospitalization period. There were no serious complications, but 1 patient developed transient vocal cord paralysis, which improved 3 months after surgery. It was suggested that the microwave energy devices, Acrosurg®. Scissors S17 and Acrosurg®. Revo S15, may be more effective with respect to sealing/hemostasis/coagulation capacity and controllability than the high-frequency electrosurgical device, LigaSure®.</p><p><strong>Conclusion: </strong>Based on this initial experience, VAT using surgical energy devices appeared to be a safe, effective, and minimally invasive procedure for the treatment of thyroid/parathyroid tumors. Further studies confirming these early findings are needed.</p>","PeriodicalId":9075,"journal":{"name":"Biomedicine Hub","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740150/pdf/bmh-0006-0153.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39724776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Covid-19 Impact on Macular Neovascularization and Retinal Vein Occlusion Treatment: Single-Center Experience. 新冠肺炎对黄斑新生血管形成和视网膜静脉阻塞治疗的影响:单中心经验。
Pub Date : 2021-12-08 eCollection Date: 2021-09-01 DOI: 10.1159/000519565
Rodrigo Vilares-Morgado, Carolina Madeira, Ana Maria Cunha, Manuel Falcão, João Beato, Ana Catarina Pedrosa, Susana Penas, Elisete Brandão, Fernando Falcão-Reis, Ângela Carneiro

Purpose: The aim of this study was to evaluate whether the coronavirus disease 19 (COVID-19) pandemic resulted in undertreatment and subsequent loss of visual acuity (VA) in patients with macular neovascularization (MNV) or retinal vein occlusion (RVO) regularly treated with intravitreal antivascular endothelial growth factor injections.

Methods: Single-center, retrospective study of patients scheduled for treatment between March 19 and June 1, 2020, the national mandatory quarantine period. Patients' demographics, VA, and scheduled treatment during this period were reviewed via medical records. All patients were analyzed regarding treatment attendance rates. The visual impact of COVID-19 was assessed in patients who had been treated and presented a stable VA for >6 months before the beginning of the quarantine.

Results: This study included 927 eyes from 769 patients. The attendance rate increased throughout the study timeframe (p < 0.001) and correlated negatively with higher patient's age (r = -0.142; p = 0.005). Patients with age-related macular degeneration (67.6%) had lower attendance rates (p = 0.007) and were older (p < 0.001). The visual impact analysis included 400 eyes from 325 patients. The average VA variation throughout this period was -1.7 ± 8.4 ETDRS letters and was similar in different retinal pathologies (p = 0.334). VA variation did not correlate with the number of missed treatments per patient (r = 0.100; p = 0.150). The prevalence of subretinal fluid and intraretinal fluid, as well as central retinal thickness decreased significantly throughout the study period (p values of <0.001, <0.001, and 0.032, respectively).

Conclusion: The COVID-19 pandemic had a significant impact on the attendance rate of patients with MNV or RVO to their scheduled treatments, which was higher in the first week of mandatory quarantine. Nevertheless, VA did not decrease significantly during this period, with a limited VA variation regardless of primary retinal disorder and morphological parameters even improved in the eyes included in the visual impact analysis.

目的:本研究的目的是评估冠状病毒病19 (COVID-19)大流行是否导致黄斑新生血管(MNV)或视网膜静脉闭塞(RVO)患者定期接受玻璃体内抗血管内皮生长因子注射治疗的治疗不足和随后的视力丧失(VA)。方法:对2020年3月19日至2020年6月1日国家强制隔离期间就诊的患者进行单中心回顾性研究。在此期间,通过医疗记录对患者的人口统计、VA和计划治疗进行了审查。分析所有患者的治疗出勤率。在隔离开始前6个月以上接受治疗并出现稳定VA的患者中,评估了COVID-19的视觉影响。结果:本研究纳入769例患者927只眼。出勤率在整个研究期间呈上升趋势(p < 0.001),且与患者年龄越高呈负相关(r = -0.142;P = 0.005)。年龄相关性黄斑变性患者(67.6%)的出勤率较低(p = 0.007)且年龄较大(p < 0.001)。视觉影响分析包括325名患者的400只眼睛。这一时期的平均VA变化为-1.7±8.4 ETDRS字母,在不同的视网膜病理中相似(p = 0.334)。VA变化与每位患者的错过治疗次数无关(r = 0.100;P = 0.150)。结论:新冠肺炎大流行对MNV或RVO患者的计划治疗出勤率有显著影响,在强制隔离的第一周更高。然而,在此期间,VA并没有显著下降,无论原发性视网膜疾病和视觉影响分析中包括的眼睛的形态学参数,VA变化有限,甚至有所改善。
{"title":"Covid-19 Impact on Macular Neovascularization and Retinal Vein Occlusion Treatment: Single-Center Experience.","authors":"Rodrigo Vilares-Morgado,&nbsp;Carolina Madeira,&nbsp;Ana Maria Cunha,&nbsp;Manuel Falcão,&nbsp;João Beato,&nbsp;Ana Catarina Pedrosa,&nbsp;Susana Penas,&nbsp;Elisete Brandão,&nbsp;Fernando Falcão-Reis,&nbsp;Ângela Carneiro","doi":"10.1159/000519565","DOIUrl":"https://doi.org/10.1159/000519565","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to evaluate whether the coronavirus disease 19 (COVID-19) pandemic resulted in undertreatment and subsequent loss of visual acuity (VA) in patients with macular neovascularization (MNV) or retinal vein occlusion (RVO) regularly treated with intravitreal antivascular endothelial growth factor injections.</p><p><strong>Methods: </strong>Single-center, retrospective study of patients scheduled for treatment between March 19 and June 1, 2020, the national mandatory quarantine period. Patients' demographics, VA, and scheduled treatment during this period were reviewed via medical records. All patients were analyzed regarding treatment attendance rates. The visual impact of COVID-19 was assessed in patients who had been treated and presented a stable VA for >6 months before the beginning of the quarantine.</p><p><strong>Results: </strong>This study included 927 eyes from 769 patients. The attendance rate increased throughout the study timeframe (<i>p</i> < 0.001) and correlated negatively with higher patient's age (<i>r</i> = -0.142; <i>p</i> = 0.005). Patients with age-related macular degeneration (67.6%) had lower attendance rates (<i>p</i> = 0.007) and were older (<i>p</i> < 0.001). The visual impact analysis included 400 eyes from 325 patients. The average VA variation throughout this period was -1.7 ± 8.4 ETDRS letters and was similar in different retinal pathologies (<i>p</i> = 0.334). VA variation did not correlate with the number of missed treatments per patient (<i>r</i> = 0.100; <i>p</i> = 0.150). The prevalence of subretinal fluid and intraretinal fluid, as well as central retinal thickness decreased significantly throughout the study period (<i>p</i> values of <0.001, <0.001, and 0.032, respectively).</p><p><strong>Conclusion: </strong>The COVID-19 pandemic had a significant impact on the attendance rate of patients with MNV or RVO to their scheduled treatments, which was higher in the first week of mandatory quarantine. Nevertheless, VA did not decrease significantly during this period, with a limited VA variation regardless of primary retinal disorder and morphological parameters even improved in the eyes included in the visual impact analysis.</p>","PeriodicalId":9075,"journal":{"name":"Biomedicine Hub","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740216/pdf/bmh-0006-0145.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39724774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic Analysis of Acid β-Glucosidase in Patients with Multiple Myeloma from Central Taiwan: A Small-Cohort Case-Control Study. 台湾中部地区多发性骨髓瘤患者酸β-葡萄糖苷酶基因分析:一项小队列病例对照研究。
Pub Date : 2021-11-29 eCollection Date: 2021-09-01 DOI: 10.1159/000519704
Wei-De Lin, Fuu-Jen Tsai

Introduction: Multiple myeloma (MM) is an incurable, biologically heterogeneous disease of the plasma cells, associated with older age and is more common in men. Gaucher disease, caused by mutation in acid β-glucosidase (glucocerebrosidase, GBA) gene, has been linked to multiple cancers, especially MM. Pathological accumulation of glucosylceramide and complex glycosphingolipids coupled with chronic inflammation may be the cause of cancer in patients with Gaucher disease. In this study, we hypothesized patients with MM have mutations in the GBA gene and analyzed patients with MM to determine whether they have a higher frequency of GBA variants.

Methods: Twenty-four MM samples were acquired from the Human Biobank, China Medical University Hospital, Taichung, Taiwan. GBA mutations were detected by polymerase chain reaction-directed DNA sequencing.

Results: We found no mutations in the coding regions of GBA in any of the 24 study subjects. However, two single-nucleotide polymorphisms, rs2070679 and rs2361534, were identified. A significant difference was observed between the study and control groups (p = 0.0028) in rs2361534 allele distribution, with the C allele frequency being higher in patients (1/48, 2.1%) than in the control group (5/3030, 0.16%, Taiwan Biobank).

Conclusion: In this study, the sample size was limited and GBA enzyme activity was not measured; therefore, we could not establish a direct correlation between MM and GBA mutations. However, the association of rs2361534 suggests that regions around this single-nucleotide polymorphism may be involved in MM. The relationship between MM and GBA mutations remains unclear. A large sample is required for a detailed analysis of this potential relationship.

简介:多发性骨髓瘤(MM)是一种无法治愈的、生物异质性的浆细胞疾病,与年龄有关,多见于男性。戈谢病是由酸性β-葡萄糖苷酶(glucocerebrosidase, GBA)基因突变引起的,与多种癌症,特别是MM有关。葡萄糖神经酰胺和复合鞘糖脂的病理性积累加上慢性炎症可能是戈谢病患者癌症的原因。在本研究中,我们假设MM患者有GBA基因突变,并对MM患者进行分析,以确定他们是否有更高频率的GBA变异。方法:24份MM标本取自台湾台中中国医科大学医院人体生物库。采用聚合酶链反应定向DNA测序检测GBA突变。结果:我们在24名研究对象中均未发现GBA编码区突变。然而,鉴定出两个单核苷酸多态性rs2070679和rs2361534。rs2361534等位基因分布与对照组比较差异有统计学意义(p = 0.0028),且患者C等位基因频率(1/48,2.1%)高于对照组(5/3030,0.16%,台湾生物库)。结论:本研究样本量有限,未测定GBA酶活性;因此,我们无法建立MM和GBA突变之间的直接相关性。然而,rs2361534的关联表明,这种单核苷酸多态性周围的区域可能与MM有关。MM与GBA突变之间的关系尚不清楚。要详细分析这种潜在的关系,需要大量的样本。
{"title":"Genetic Analysis of Acid β-Glucosidase in Patients with Multiple Myeloma from Central Taiwan: A Small-Cohort Case-Control Study.","authors":"Wei-De Lin,&nbsp;Fuu-Jen Tsai","doi":"10.1159/000519704","DOIUrl":"https://doi.org/10.1159/000519704","url":null,"abstract":"<p><strong>Introduction: </strong>Multiple myeloma (MM) is an incurable, biologically heterogeneous disease of the plasma cells, associated with older age and is more common in men. Gaucher disease, caused by mutation in acid β-glucosidase (glucocerebrosidase, <i>GBA</i>) gene, has been linked to multiple cancers, especially MM. Pathological accumulation of glucosylceramide and complex glycosphingolipids coupled with chronic inflammation may be the cause of cancer in patients with Gaucher disease. In this study, we hypothesized patients with MM have mutations in the <i>GBA</i> gene and analyzed patients with MM to determine whether they have a higher frequency of <i>GBA</i> variants.</p><p><strong>Methods: </strong>Twenty-four MM samples were acquired from the Human Biobank, China Medical University Hospital, Taichung, Taiwan. <i>GBA</i> mutations were detected by polymerase chain reaction-directed DNA sequencing.</p><p><strong>Results: </strong>We found no mutations in the coding regions of <i>GBA</i> in any of the 24 study subjects. However, two single-nucleotide polymorphisms, rs2070679 and rs2361534, were identified. A significant difference was observed between the study and control groups (<i>p</i> = 0.0028) in rs2361534 allele distribution, with the C allele frequency being higher in patients (1/48, 2.1%) than in the control group (5/3030, 0.16%, Taiwan Biobank).</p><p><strong>Conclusion: </strong>In this study, the sample size was limited and GBA enzyme activity was not measured; therefore, we could not establish a direct correlation between MM and <i>GBA</i> mutations. However, the association of rs2361534 suggests that regions around this single-nucleotide polymorphism may be involved in MM. The relationship between MM and <i>GBA</i> mutations remains unclear. A large sample is required for a detailed analysis of this potential relationship.</p>","PeriodicalId":9075,"journal":{"name":"Biomedicine Hub","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740171/pdf/bmh-0006-0138.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39724773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of Baicalin toward COVID-19 Treatment: In silico Target Analysis and in vitro Inhibitory Effects on SARS-CoV-2 Proteases. 黄芩苷治疗COVID-19的研究:硅靶分析及对SARS-CoV-2蛋白酶的体外抑制作用
Pub Date : 2021-11-12 eCollection Date: 2021-09-01 DOI: 10.1159/000519564
Chingju Lin, Fuu-Jen Tsai, Yuan-Man Hsu, Tsung-Jung Ho, Guo-Kai Wang, Yu-Jen Chiu, Hai-Anh Ha, Jai-Sing Yang

Negative impacts of COVID-19 on human health and economic and social activities urge scientists to develop effective treatments. Baicalin is a natural flavonoid, extracted from a traditional medicinal plant, previously reported with anti-inflammatory activity. In this study, we used pharmacophore fitting and molecular docking to screen and determine docking patterns and the binding affinity of baicalin on 3 major targets of SARS-CoV-2 (3-chymotrypsin-like cysteine protease [3CLpro], papain-like protease [PLpro], and RNA-dependent RNA polymerase). The obtained data revealed that baicalin has high pharmacophore fitting on 3CLpro and predicted good binding affinity on PLpro. Moreover, using the enzymatic assay, we examined the inhibitory effect of baicalin in vitro on the screened enzymes. Baicalin also exhibits inhibitory effect on these proteases in vitro. Additionally, we performed pharmacophore-based screening of baicalin on human targets and conducted pathway analysis to explore the potential cytoprotective effects of baicalin in the host cell that may be beneficial for COVID-19 treatment. The result suggested that baicalin has multiple targets in human cell that may induce multiple pharmacological effects. The result of pathway analysis implied that these targets may be associated with baicalin-induced bioactivities that are involved with signals of pro-inflammation factors, such as cytokine and chemokine. Taken together with supportive data from the literature, the bioactivities of bailalin may be beneficial for COVID-19 treatment by reducing cytokine-induced acute inflammation. In conclusion, baicalin is potentially a good candidate for developing new therapeutic to treat COVID-19.

COVID-19对人类健康和经济社会活动的负面影响促使科学家开发有效的治疗方法。黄芩苷是一种从传统药用植物中提取的天然黄酮类化合物,具有抗炎活性。本研究采用药效团拟合和分子对接的方法,筛选并确定黄芩苷与SARS-CoV-2 3个主要靶点(3-凝血胰蛋白酶样半胱氨酸蛋白酶[3CLpro]、木瓜蛋白酶样蛋白酶[PLpro]和RNA依赖性RNA聚合酶)的对接模式和结合亲和力。结果表明,黄芩苷对3CLpro具有较高的药效团拟合性,与PLpro具有良好的结合亲和力。此外,采用酶促法考察了黄芩苷对筛选出的酶的体外抑制作用。黄芩苷对这些蛋白酶也有抑制作用。此外,我们对黄芩苷进行了基于药物团的人体靶点筛选,并进行了途径分析,以探索黄芩苷在宿主细胞中的潜在细胞保护作用,可能有助于治疗COVID-19。提示黄芩苷在人体细胞中具有多个靶点,可诱导多种药理作用。通路分析结果提示,这些靶点可能与黄芩苷诱导的促炎因子(如细胞因子和趋化因子)的信号有关。结合文献中的支持性数据,bailalin的生物活性可能通过减少细胞因子诱导的急性炎症而有利于COVID-19的治疗。综上所述,黄芩苷具有开发新型药物治疗新冠肺炎的潜力。
{"title":"Study of Baicalin toward COVID-19 Treatment: In silico Target Analysis and in vitro Inhibitory Effects on SARS-CoV-2 Proteases.","authors":"Chingju Lin,&nbsp;Fuu-Jen Tsai,&nbsp;Yuan-Man Hsu,&nbsp;Tsung-Jung Ho,&nbsp;Guo-Kai Wang,&nbsp;Yu-Jen Chiu,&nbsp;Hai-Anh Ha,&nbsp;Jai-Sing Yang","doi":"10.1159/000519564","DOIUrl":"https://doi.org/10.1159/000519564","url":null,"abstract":"<p><p>Negative impacts of COVID-19 on human health and economic and social activities urge scientists to develop effective treatments. Baicalin is a natural flavonoid, extracted from a traditional medicinal plant, previously reported with anti-inflammatory activity. In this study, we used pharmacophore fitting and molecular docking to screen and determine docking patterns and the binding affinity of baicalin on 3 major targets of SARS-CoV-2 (3-chymotrypsin-like cysteine protease [3CLpro], papain-like protease [PLpro], and RNA-dependent RNA polymerase). The obtained data revealed that baicalin has high pharmacophore fitting on 3CLpro and predicted good binding affinity on PLpro. Moreover, using the enzymatic assay, we examined the inhibitory effect of baicalin in vitro on the screened enzymes. Baicalin also exhibits inhibitory effect on these proteases in vitro. Additionally, we performed pharmacophore-based screening of baicalin on human targets and conducted pathway analysis to explore the potential cytoprotective effects of baicalin in the host cell that may be beneficial for COVID-19 treatment. The result suggested that baicalin has multiple targets in human cell that may induce multiple pharmacological effects. The result of pathway analysis implied that these targets may be associated with baicalin-induced bioactivities that are involved with signals of pro-inflammation factors, such as cytokine and chemokine. Taken together with supportive data from the literature, the bioactivities of bailalin may be beneficial for COVID-19 treatment by reducing cytokine-induced acute inflammation. In conclusion, baicalin is potentially a good candidate for developing new therapeutic to treat COVID-19.</p>","PeriodicalId":9075,"journal":{"name":"Biomedicine Hub","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fe/ad/bmh-0006-0122.PMC8647113.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39747038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Prescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide? 重度抑郁症的处方药物治疗:临床医生如何决定?
Pub Date : 2021-11-01 eCollection Date: 2021-09-01 DOI: 10.1159/000519656
Fiammetta Cosci, Giovanni A Fava
a Department of Health Sciences, University of Florence, Florence, Italy; b Clinical Pharmacopsychology Laboratory, University of Florence, Florence, Italy; c Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands; d Department of Psychiatry, University at Buffalo, State University of New York, Buffalo, NY, USA Received: September 9, 2021 Accepted: September 13, 2021 Published online: November 1, 2021
{"title":"Prescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide?","authors":"Fiammetta Cosci,&nbsp;Giovanni A Fava","doi":"10.1159/000519656","DOIUrl":"https://doi.org/10.1159/000519656","url":null,"abstract":"a Department of Health Sciences, University of Florence, Florence, Italy; b Clinical Pharmacopsychology Laboratory, University of Florence, Florence, Italy; c Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands; d Department of Psychiatry, University at Buffalo, State University of New York, Buffalo, NY, USA Received: September 9, 2021 Accepted: September 13, 2021 Published online: November 1, 2021","PeriodicalId":9075,"journal":{"name":"Biomedicine Hub","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/64/bmh-0006-0118.PMC8647051.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39759134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Prevalence of Chronic Metabolic Comorbidities in Acute Pancreatitis and Its Impact on Early Gastrointestinal Symptoms during Hospitalization: A Prospective Cohort Study. 急性胰腺炎慢性代谢合并症的患病率及其对住院期间早期胃肠道症状的影响:一项前瞻性队列研究
Pub Date : 2021-11-01 eCollection Date: 2021-09-01 DOI: 10.1159/000519826
Rachel Goodger, Kanageswari Singaram, Maxim S Petrov

Background: The prevalence of chronic comorbidities is increasing worldwide, and this has been paralleled by a growing interest in how these comorbidities affect patients with acute pancreatitis. The aim was to investigate the associations between pre-existing diabetes mellitus, obesity, metabolic syndrome, and gastrointestinal symptoms during the early course of acute pancreatitis.

Methods: This was a prospective cohort study of patients with a primary diagnosis of acute pancreatitis. Study groups were formed based on the presence of metabolic comorbidities (pre-existing diabetes mellitus, obesity, and metabolic syndrome). Patient-reported outcomes (nausea, bloating, and abdominal pain) were collected prospectively every 24 h (including weekends and public holidays) over the first 72 h of hospitalization.

Results: A total of 183 consecutive patients were enrolled. Of them, 111 (61%) had at least one major metabolic comorbidity. Patients with pre-existing diabetes mellitus and those with metabolic syndrome had worse nausea at 49-72 h of hospitalization (p = 0.017 and p = 0.012, respectively), but not at other time points. Bloating and abdominal pain did not differ between the study groupings throughout the study period. The studied patient-reported outcomes did not differ significantly between acute pancreatitis patients with and without obesity at any point in time.

Conclusion: More than 3 out of 5 patients hospitalized for acute pancreatitis have at least one major chronic metabolic comorbidity. The presence of metabolic comorbidities does not considerably and consistently affect early gastrointestinal symptoms in patients with acute pancreatitis.

背景:慢性合并症的患病率在世界范围内正在增加,与此同时,人们对这些合并症如何影响急性胰腺炎患者也越来越感兴趣。目的是研究急性胰腺炎早期存在的糖尿病、肥胖、代谢综合征和胃肠道症状之间的关系。方法:这是一项对初步诊断为急性胰腺炎的患者进行的前瞻性队列研究。研究组是根据代谢合并症(先前存在的糖尿病、肥胖和代谢综合征)的存在而形成的。在住院的前72小时内,每24小时(包括周末和公众假期)前瞻性地收集患者报告的结局(恶心、腹胀和腹痛)。结果:共有183名连续患者入组。其中111例(61%)至少有一种主要的代谢合并症。合并糖尿病和代谢综合征的患者在住院49 ~ 72 h恶心加重(p = 0.017和p = 0.012),而在其他时间点则无明显差异。在整个研究期间,腹胀和腹痛在研究组之间没有差异。在任何时间点上,患者报告的结果在伴有和不伴有肥胖的急性胰腺炎患者之间没有显著差异。结论:超过3 / 5的急性胰腺炎住院患者至少有一种主要的慢性代谢合并症。代谢合并症的存在对急性胰腺炎患者的早期胃肠道症状没有显著和持续的影响。
{"title":"Prevalence of Chronic Metabolic Comorbidities in Acute Pancreatitis and Its Impact on Early Gastrointestinal Symptoms during Hospitalization: A Prospective Cohort Study.","authors":"Rachel Goodger,&nbsp;Kanageswari Singaram,&nbsp;Maxim S Petrov","doi":"10.1159/000519826","DOIUrl":"https://doi.org/10.1159/000519826","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of chronic comorbidities is increasing worldwide, and this has been paralleled by a growing interest in how these comorbidities affect patients with acute pancreatitis. The aim was to investigate the associations between pre-existing diabetes mellitus, obesity, metabolic syndrome, and gastrointestinal symptoms during the early course of acute pancreatitis.</p><p><strong>Methods: </strong>This was a prospective cohort study of patients with a primary diagnosis of acute pancreatitis. Study groups were formed based on the presence of metabolic comorbidities (pre-existing diabetes mellitus, obesity, and metabolic syndrome). Patient-reported outcomes (nausea, bloating, and abdominal pain) were collected prospectively every 24 h (including weekends and public holidays) over the first 72 h of hospitalization.</p><p><strong>Results: </strong>A total of 183 consecutive patients were enrolled. Of them, 111 (61%) had at least one major metabolic comorbidity. Patients with pre-existing diabetes mellitus and those with metabolic syndrome had worse nausea at 49-72 h of hospitalization (<i>p</i> = 0.017 and <i>p</i> = 0.012, respectively), but not at other time points. Bloating and abdominal pain did not differ between the study groupings throughout the study period. The studied patient-reported outcomes did not differ significantly between acute pancreatitis patients with and without obesity at any point in time.</p><p><strong>Conclusion: </strong>More than 3 out of 5 patients hospitalized for acute pancreatitis have at least one major chronic metabolic comorbidity. The presence of metabolic comorbidities does not considerably and consistently affect early gastrointestinal symptoms in patients with acute pancreatitis.</p>","PeriodicalId":9075,"journal":{"name":"Biomedicine Hub","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/28/bmh-0006-0111.PMC8647128.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39759132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
A Longitudinal Study on the Mental Health of College Students in Jinan During the Peak Stage of the COVID-19 Epidemic and the Society Reopening. 新冠肺炎疫情高峰期与社会重新开放时期济南市大学生心理健康的纵向研究
Pub Date : 2021-10-12 eCollection Date: 2021-09-01 DOI: 10.1159/000519586
Xiaolei Zheng, Yuji Guo, Wen Ma, Hui Yang, Liyan Luo, Li Wen, Xiaolan Zhou, Qing Li, Jianzhong Bi, Ping Wang, Hongxing Wang

Introduction: COVID-19, a continuously emerging human-to-human infectious disease, has exerted a significant impact on the mental health of college students. However, little is known regarding the variations in the mental health issues experienced by college students during the peak versus reopening stages of the COVID-19 epidemic in China.

Methods: To assess these issues, an online longitudinal survey was conducted via a WeChat applet. Undergraduates (n = 300) were recruited from 26 universities throughout Jinan in February 2020 (T1 - the epidemic peak stage) and in January 2021 (T2 - the society reopening stage). Their mental status was determined using the Patient Health Questionnaire-9, the Generalized Anxiety Disorder-7 item, and the Insomnia Severity Index.

Results: Of the original 300 college students recruited for this survey, 294 responses at T1 and 285 at T2 were analyzed. Compared with responses obtained at T1, college students at T2 showed a greater prevalence of depression (65.3 vs. 51.0%; p = 0.001) and anxiety (47.7 vs. 38.1%, p = 0.019), and experienced more severe depression (p < 0.001) and anxiety (p < 0.001). Both males (p = 0.03) and females (p < 0.01) showed higher levels of depression at T2 versus T1, while no differences were obtained with regard to anxiety and insomnia. At T1, Grade 4 students showed greater levels of depression (p = 0.005) and anxiety (p = 0.008) than that of Grade 1 students. While at T2, only greater levels of depression (p = 0.004) were present when compared with that of Grade 1 students. Additionally, Grade 4 college students demonstrated a greater prevalence of depression at T2 versus T1 (p = 0.03), but no statistically differences were present for anxiety and insomnia. No statistically significant differences were obtained among the 4 grades of college students for insomnia at either the T1 or T2.

Conclusion: With progression of the COVID-19 epidemic, college students showed increasing levels of depression and anxiety, with Grade 4 college students being most seriously affected. It is imperative that intervention strategies be implemented to mitigate against these mental health issues resulting from the COVID-19 epidemic.

导读:新型冠状病毒病(COVID-19)是一种不断出现的人际传染病,对大学生的心理健康产生了重大影响。然而,关于中国大学生在COVID-19疫情高峰期和重新开放阶段所经历的心理健康问题的差异,人们知之甚少。方法:为了评估这些问题,通过微信小程序进行了在线纵向调查。于2020年2月(T1 -疫情高峰阶段)和2021年1月(T2 -社会复工阶段)在济南市26所高校招收本科生300人。他们的精神状态是通过患者健康问卷-9、广泛性焦虑障碍-7和失眠严重程度指数来确定的。结果:在最初的300名大学生中,分析了T1的294份和T2的285份。与T1时相比,T2时大学生的抑郁患病率更高(65.3比51.0%;P = 0.001)和焦虑(47.7% vs. 38.1%, P = 0.019),抑郁(P < 0.001)和焦虑(P < 0.001)更严重。与T1相比,男性(p = 0.03)和女性(p < 0.01)在T2时均表现出更高的抑郁水平,而在焦虑和失眠方面没有差异。T1时,四年级学生的抑郁水平(p = 0.005)和焦虑水平(p = 0.008)高于一年级学生。而在T2阶段,与一年级学生相比,只有更高的抑郁水平(p = 0.004)。此外,与T1相比,四年级学生在T2时表现出更大的抑郁患病率(p = 0.03),但在焦虑和失眠方面没有统计学差异。4个年级大学生在T1和T2阶段的失眠情况差异均无统计学意义。结论:随着新冠肺炎疫情的发展,大学生抑郁和焦虑水平呈上升趋势,以四年级学生受影响最为严重。必须实施干预战略,以减轻COVID-19流行病造成的这些心理健康问题。
{"title":"A Longitudinal Study on the Mental Health of College Students in Jinan During the Peak Stage of the COVID-19 Epidemic and the Society Reopening.","authors":"Xiaolei Zheng,&nbsp;Yuji Guo,&nbsp;Wen Ma,&nbsp;Hui Yang,&nbsp;Liyan Luo,&nbsp;Li Wen,&nbsp;Xiaolan Zhou,&nbsp;Qing Li,&nbsp;Jianzhong Bi,&nbsp;Ping Wang,&nbsp;Hongxing Wang","doi":"10.1159/000519586","DOIUrl":"https://doi.org/10.1159/000519586","url":null,"abstract":"<p><strong>Introduction: </strong>COVID-19, a continuously emerging human-to-human infectious disease, has exerted a significant impact on the mental health of college students. However, little is known regarding the variations in the mental health issues experienced by college students during the peak versus reopening stages of the COVID-19 epidemic in China.</p><p><strong>Methods: </strong>To assess these issues, an online longitudinal survey was conducted via a WeChat applet. Undergraduates (<i>n</i> = 300) were recruited from 26 universities throughout Jinan in February 2020 (T1 - the epidemic peak stage) and in January 2021 (T2 - the society reopening stage). Their mental status was determined using the Patient Health Questionnaire-9, the Generalized Anxiety Disorder-7 item, and the Insomnia Severity Index.</p><p><strong>Results: </strong>Of the original 300 college students recruited for this survey, 294 responses at T1 and 285 at T2 were analyzed. Compared with responses obtained at T1, college students at T2 showed a greater prevalence of depression (65.3 vs. 51.0%; <i>p</i> = 0.001) and anxiety (47.7 vs. 38.1%, <i>p</i> = 0.019), and experienced more severe depression (<i>p</i> < 0.001) and anxiety (<i>p</i> < 0.001). Both males (<i>p</i> = 0.03) and females (<i>p</i> < 0.01) showed higher levels of depression at T2 versus T1, while no differences were obtained with regard to anxiety and insomnia. At T1, Grade 4 students showed greater levels of depression (<i>p</i> = 0.005) and anxiety (<i>p</i> = 0.008) than that of Grade 1 students. While at T2, only greater levels of depression (<i>p</i> = 0.004) were present when compared with that of Grade 1 students. Additionally, Grade 4 college students demonstrated a greater prevalence of depression at T2 versus T1 (<i>p</i> = 0.03), but no statistically differences were present for anxiety and insomnia. No statistically significant differences were obtained among the 4 grades of college students for insomnia at either the T1 or T2.</p><p><strong>Conclusion: </strong>With progression of the COVID-19 epidemic, college students showed increasing levels of depression and anxiety, with Grade 4 college students being most seriously affected. It is imperative that intervention strategies be implemented to mitigate against these mental health issues resulting from the COVID-19 epidemic.</p>","PeriodicalId":9075,"journal":{"name":"Biomedicine Hub","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/5c/bmh-0006-0102.PMC8613590.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39847960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 34
The Value of a Systematic Protocol Using Endobronchial Ultrasound and Endoscopic Ultrasound in Staging of Lung Cancer for Patients with Imaging iN0-N1 Disease. 支气管内超声和内镜下超声系统方案在影像学为iN0-N1的肺癌患者分期中的价值
Pub Date : 2021-10-08 eCollection Date: 2021-09-01 DOI: 10.1159/000519034
Rosa Cordovilla, Marco López-Zubizarreta, Antonio Velasco, Alberto Álvarez, Marta Rodríguez, Asunción Gómez, Miguel Ángel Hernández-Mezquita, Miguel Iglesias

Introduction: We hypothesize that systematic, combined, and multidisciplinary study of the mediastinum (endobronchial ultrasound [EBUS] and endoscopic ultrasound [EUS]) in patients with NSCLC with radiologically normal mediastinum improves the results of mediastinal staging obtained with EBUS alone.

Material and methods: A retrospective study of the prospective database collected on the patients with NSCLC with a radiologically normal mediastinum and an indication for systematic staging with EBUS and EUS. EBUS staging was followed by EUS in patients in which the results from the pathological analysis of EBUS were negative.

Results: Forty-five patients were included in the analysis. The combination of EBUS followed by EUS provided better results than EBUS alone: sensitivity (S) 95% versus 80%, negative predictive value (NPV) 96.15% versus 86.21%, negative likelihood ratio 0.05 versus 0.20, and post-test probability 3.8% versus 13.8%. This represents an increase in S (15%), the validity index (6.6%), and NPV (9.9%) compared to EBUS alone. There were 4 false negatives (FNs) (8.8%) with the EBUS test alone. After adding EUS, 3 more cases were positive (6.6%) and only 1 FN (2.2%).

Conclusions: In patients with NSCLC and a radiographically normal mediastinum, a systematic and combined staging with EBUS and EUS show higher sensitivity in the detection of mediastinal metastasis than with the use of EBUS alone. The high accuracy of the test means that the use of mediastinoscopy is not necessary to confirm the results in these patients. Since the availability of EUS is low, it may be advisable for the interventional pulmonologist to receive training in EUS-b.

我们假设系统、联合和多学科的研究(支气管超声[EBUS]和内镜超声[EUS])对放射学上正常的NSCLC纵隔患者的纵隔分期可以改善单独使用EBUS获得的纵隔分期结果。材料和方法:回顾性研究收集的纵隔放射学正常的NSCLC患者的前瞻性数据库,并采用EBUS和EUS进行系统分期。病理分析结果为阴性的患者进行EBUS分期并进行EUS检查。结果:45例患者纳入分析。EBUS联合EUS优于单独EBUS:敏感性(S) 95% vs 80%,阴性预测值(NPV) 96.15% vs 86.21%,阴性似然比0.05 vs 0.20,验后概率3.8% vs 13.8%。与单独的EBUS相比,这代表了S(15%)、有效性指数(6.6%)和NPV(9.9%)的增加。单独使用EBUS检测出现4例假阴性(FNs),占8.8%。加EUS后阳性3例(6.6%),FN仅1例(2.2%)。结论:在影像学正常的非小细胞肺癌纵隔患者中,与单独使用EBUS相比,系统和联合分期EBUS和EUS在检测纵隔转移方面具有更高的敏感性。测试的高准确性意味着在这些患者中不需要使用纵隔镜检查来确认结果。由于EUS的可用性较低,介入肺科医生接受EUS-b培训可能是可取的。
{"title":"The Value of a Systematic Protocol Using Endobronchial Ultrasound and Endoscopic Ultrasound in Staging of Lung Cancer for Patients with Imaging iN0-N1 Disease.","authors":"Rosa Cordovilla,&nbsp;Marco López-Zubizarreta,&nbsp;Antonio Velasco,&nbsp;Alberto Álvarez,&nbsp;Marta Rodríguez,&nbsp;Asunción Gómez,&nbsp;Miguel Ángel Hernández-Mezquita,&nbsp;Miguel Iglesias","doi":"10.1159/000519034","DOIUrl":"https://doi.org/10.1159/000519034","url":null,"abstract":"<p><strong>Introduction: </strong>We hypothesize that systematic, combined, and multidisciplinary study of the mediastinum (endobronchial ultrasound [EBUS] and endoscopic ultrasound [EUS]) in patients with NSCLC with radiologically normal mediastinum improves the results of mediastinal staging obtained with EBUS alone.</p><p><strong>Material and methods: </strong>A retrospective study of the prospective database collected on the patients with NSCLC with a radiologically normal mediastinum and an indication for systematic staging with EBUS and EUS. EBUS staging was followed by EUS in patients in which the results from the pathological analysis of EBUS were negative.</p><p><strong>Results: </strong>Forty-five patients were included in the analysis. The combination of EBUS followed by EUS provided better results than EBUS alone: sensitivity (S) 95% versus 80%, negative predictive value (NPV) 96.15% versus 86.21%, negative likelihood ratio 0.05 versus 0.20, and post-test probability 3.8% versus 13.8%. This represents an increase in S (15%), the validity index (6.6%), and NPV (9.9%) compared to EBUS alone. There were 4 false negatives (FNs) (8.8%) with the EBUS test alone. After adding EUS, 3 more cases were positive (6.6%) and only 1 FN (2.2%).</p><p><strong>Conclusions: </strong>In patients with NSCLC and a radiographically normal mediastinum, a systematic and combined staging with EBUS and EUS show higher sensitivity in the detection of mediastinal metastasis than with the use of EBUS alone. The high accuracy of the test means that the use of mediastinoscopy is not necessary to confirm the results in these patients. Since the availability of EUS is low, it may be advisable for the interventional pulmonologist to receive training in EUS-b.</p>","PeriodicalId":9075,"journal":{"name":"Biomedicine Hub","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/19/9a/bmh-0006-0092.PMC8613614.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39847959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in the Intra-Amniotic Pressure following Transabdominal Amnioinfusion during Pregnancy. 妊娠期经腹羊膜输注后羊膜内压力的变化。
Pub Date : 2021-10-05 eCollection Date: 2021-09-01 DOI: 10.1159/000519084
Daisuke Katsura, Yuichiro Takahashi, Shigenori Iwagaki, Rika Chiaki, Kazuhiko Asai, Masako Koike, Takashi Murakami

Objective: The aim of the article was to investigate the changes in intra-amniotic pressure following transabdominal amnioinfusion during pregnancy.

Design: This retrospective study included 19 pregnant women who underwent transabdominal amnioinfusion during pregnancy to relieve umbilical cord compression and improve the intrauterine environment or to increase the accuracy of ultrasonography.

Materials and methods: We measured and analyzed the changes in intra-amniotic pressure, single deepest pocket, and the amniotic fluid index before and after amnioinfusion. We also determined the incidence of maternal or fetal adverse events, such as preterm premature rupture of membranes, preterm delivery, fetal death within 48 h, placental abruption, infection, hemorrhage, and peripheral organ injury.

Results: A total of 41 amnioinfusion procedures were performed for 19 patients. The median gestational age during the procedure was 24.3 weeks. The median volume of the injected amniotic fluid was 250 mL. The median single deepest pocket and amniotic fluid index after amnioinfusion were significantly higher than those before amnioinfusion (4.0 cm vs. 2.65 cm; p < 0.001 and 13.4 cm vs. 6.0 cm; p < 0.001). However, the median (range) intra-amniotic pressure after amnioinfusion was not significantly different compared to that before amnioinfusion (11 mm Hg vs. 11 mm Hg; p = 0.134). Maternal or fetal adverse events were not observed following amnioinfusion.

Conclusion: Intra-amniotic pressure remained unchanged following amnioinfusion. The complications associated with increased intra-amniotic pressure are not likely to develop if the amniotic fluid index and/or single deepest pocket remains within the normal range after amnioinfusion. Studies of groups with and without complications are warranted to clarify the relationship between the intra-amniotic pressure and incidence of complications.

目的:探讨妊娠期经腹羊膜输注后羊膜内压力的变化。设计:本回顾性研究纳入19例孕妇,目的是缓解脐带压迫,改善宫内环境或提高超声检查的准确性。材料与方法:测定并分析羊膜输注前后羊膜内压力、单最深袋、羊水指数的变化。我们还确定了母体或胎儿不良事件的发生率,如早产、胎膜早破、早产、48小时内胎儿死亡、胎盘早剥、感染、出血和外周器官损伤。结果:19例患者共行41次羊膜输注手术。手术期间的中位胎龄为24.3周。羊水注射容积中位数为250 mL,羊水输注后单最深袋中位数和羊水指数均显著高于羊水输注前(4.0 cm vs. 2.65 cm;P < 0.001, 13.4 cm vs. 6.0 cm;P < 0.001)。然而,羊膜输注后羊膜内压中位(范围)与羊膜输注前无显著差异(11 mm Hg vs 11 mm Hg;P = 0.134)。羊膜输注后未观察到母体或胎儿的不良事件。结论:羊膜输注后羊膜内压力保持不变。如果羊水指数和/或单个最深口袋在羊水注入后保持在正常范围内,则羊水压力升高相关的并发症不太可能发生。有和无并发症组的研究是必要的,以澄清羊膜内压力和并发症发生率之间的关系。
{"title":"Changes in the Intra-Amniotic Pressure following Transabdominal Amnioinfusion during Pregnancy.","authors":"Daisuke Katsura,&nbsp;Yuichiro Takahashi,&nbsp;Shigenori Iwagaki,&nbsp;Rika Chiaki,&nbsp;Kazuhiko Asai,&nbsp;Masako Koike,&nbsp;Takashi Murakami","doi":"10.1159/000519084","DOIUrl":"https://doi.org/10.1159/000519084","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the article was to investigate the changes in intra-amniotic pressure following transabdominal amnioinfusion during pregnancy.</p><p><strong>Design: </strong>This retrospective study included 19 pregnant women who underwent transabdominal amnioinfusion during pregnancy to relieve umbilical cord compression and improve the intrauterine environment or to increase the accuracy of ultrasonography.</p><p><strong>Materials and methods: </strong>We measured and analyzed the changes in intra-amniotic pressure, single deepest pocket, and the amniotic fluid index before and after amnioinfusion. We also determined the incidence of maternal or fetal adverse events, such as preterm premature rupture of membranes, preterm delivery, fetal death within 48 h, placental abruption, infection, hemorrhage, and peripheral organ injury.</p><p><strong>Results: </strong>A total of 41 amnioinfusion procedures were performed for 19 patients. The median gestational age during the procedure was 24.3 weeks. The median volume of the injected amniotic fluid was 250 mL. The median single deepest pocket and amniotic fluid index after amnioinfusion were significantly higher than those before amnioinfusion (4.0 cm vs. 2.65 cm; <i>p</i> < 0.001 and 13.4 cm vs. 6.0 cm; <i>p</i> < 0.001). However, the median (range) intra-amniotic pressure after amnioinfusion was not significantly different compared to that before amnioinfusion (11 mm Hg vs. 11 mm Hg; <i>p</i> = 0.134). Maternal or fetal adverse events were not observed following amnioinfusion.</p><p><strong>Conclusion: </strong>Intra-amniotic pressure remained unchanged following amnioinfusion. The complications associated with increased intra-amniotic pressure are not likely to develop if the amniotic fluid index and/or single deepest pocket remains within the normal range after amnioinfusion. Studies of groups with and without complications are warranted to clarify the relationship between the intra-amniotic pressure and incidence of complications.</p>","PeriodicalId":9075,"journal":{"name":"Biomedicine Hub","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fe/ea/bmh-0006-0086.PMC8613638.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39847958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optical Bench Analysis of 2 Depth of Focus Intraocular Lenses. 2种聚焦深度人工晶体的光学台架分析。
Pub Date : 2021-09-27 eCollection Date: 2021-09-01 DOI: 10.1159/000519139
Andreas F Borkenstein, Eva-Maria Borkenstein, Holger Luedtke, Ruediger Schmid

Background: The aim of the study was to analyze the objective optical properties of 2 enhanced depth of focus (EDoF) intraocular lenses (IOLs) using optical bench analysis.

Methods: This experimental study investigates 2 new EDoF IOLs, the Alcon AcrySof IQ Vivity and the Bausch & Lomb LuxSmart Crystal, on the optical bench, using OptiSpheric IOL PRO2 (Trioptics, Germany) in order to assess the optical quality according to ISO 11979 with ISO-2 Cornea. IOLs (power 22.0 D) were evaluated regarding modulation transfer function (MTF) at 50 lp/mm and Strehl ratio (SR) using a 3.0-mm and a 4.5-mm aperture. In addition, wavefront measurements were obtained using WaveMaster® IOL 2 device (Trioptics, Germany), and USAF targets were analyzed.

Results: Centered: the MTF (mean) at 50 lp/mm (AcrySof IQ Vivity/LuxSmart Crystal) with 3.0 mm aperture was 0.250/0.257 and with 4.5 mm aperture 0.202/0.243. The SR (mean) with 3.0 mm aperture was 0.261/0.355 and with 4.5 mm aperture 0.176/0.206. Decentered by 1 mm: the MTF (mean) at 50 lp/mm (AcrySof IQ Vivity/LuxSmart Crystal) with 3.0 mm aperture was 0.266/0.247 and with 4.5 mm aperture 0.126/0.215. The SR (mean) with 3.0 mm aperture was 0.272/0.234 and with 4.5 mm aperture 0.133/0.183. Tilted by 5 degree: the MTF (mean) at 50 lp/mm (AcrySof IQ Vivity/LuxSmart Crystal) with 3.0 mm aperture was 0.221/0.360 and with 4.5 mm aperture 0.214/0.229. The SR (mean) with 3.0 mm aperture was 0.232/0.428 and with 4.5 mm aperture 0.225/0.229. The simulated visual function using USAF test targets showed corresponding qualitative results. Wavefront measurements proved a complex optical design. Higher order aberrations in the central part of the optics were modulated up to the 10th order to enhance the range of functional vision to near distance, leaving the peripheral parts of the optics aberration free or as aberration correcting.

Conclusion: The diversity of EDOF IOLs, their optics, and their respective impact on the vision quality must be understood in order to select the appropriate IOL in each individual case. This analysis of new, innovative IOL optics based on increased negative spherical aberration may help the ophthalmic surgeon to select the IOL which meets the individual requirements of the patient for best postoperative outcomes. It seems that there is no perfect IOL that is equally suitable for all patients, but the right choice is an individual, customized approach dealing with patients' expectations.

背景:采用光学台架分析法分析2种增强聚焦深度(EDoF)人工晶体(iol)的物镜光学特性。方法:采用optisphere IOL PRO2 (Trioptics, Germany)在光学实验台上对爱尔康AcrySof IQ Vivity和Bausch & lomluxsmart Crystal两种新型EDoF IOL进行了实验研究,并根据ISO-2角膜的ISO 11979标准对光学质量进行了评估。使用3.0 mm和4.5 mm孔径对iol(功率22.0 D)在50 lp/mm下的调制传递函数(MTF)和Strehl比率(SR)进行评估。此外,使用WaveMaster®IOL 2设备(Trioptics,德国)获得波前测量,并对美国空军目标进行分析。结果:中心:3.0 mm孔径下50 lp/mm (AcrySof IQ Vivity/LuxSmart Crystal) MTF平均值为0.250/0.257,4.5 mm孔径下MTF平均值为0.202/0.243。孔径3.0 mm时的平均SR为0.261/0.355,孔径4.5 mm时的平均SR为0.176/0.206。偏心1毫米:50 lp/mm (AcrySof IQ Vivity/LuxSmart Crystal) 3.0 mm孔径下的MTF(平均值)为0.266/0.247,4.5 mm孔径下为0.126/0.215。孔径3.0 mm时的平均SR为0.272/0.234,孔径4.5 mm时的平均SR为0.133/0.183。倾斜5度:3.0 mm孔径下50 lp/mm (AcrySof IQ Vivity/LuxSmart Crystal)的MTF(平均值)为0.221/0.360,4.5 mm孔径为0.214/0.229。孔径3.0 mm时的平均SR为0.232/0.428,孔径4.5 mm时的平均SR为0.225/0.229。用美国空军测试靶模拟的视觉功能得到了相应的定性结果。波前测量证明了一种复杂的光学设计。光学元件中心部分的高阶像差被调制到10阶,以增强功能视觉的近距离范围,使光学元件的外围部分没有像差或作为像差校正。结论:必须了解EDOF人工晶状体的多样性、它们的光学特性及其对视力质量的影响,以便在每个病例中选择合适的人工晶状体。这种基于增加负球差的新型创新IOL光学分析可以帮助眼科医生选择符合患者个性化要求的IOL,以获得最佳的术后效果。似乎不存在适合所有患者的完美人工晶状体,但正确的选择是根据患者的期望进行个性化定制。
{"title":"Optical Bench Analysis of 2 Depth of Focus Intraocular Lenses.","authors":"Andreas F Borkenstein,&nbsp;Eva-Maria Borkenstein,&nbsp;Holger Luedtke,&nbsp;Ruediger Schmid","doi":"10.1159/000519139","DOIUrl":"https://doi.org/10.1159/000519139","url":null,"abstract":"<p><strong>Background: </strong>The aim of the study was to analyze the objective optical properties of 2 enhanced depth of focus (EDoF) intraocular lenses (IOLs) using optical bench analysis.</p><p><strong>Methods: </strong>This experimental study investigates 2 new EDoF IOLs, the Alcon AcrySof IQ Vivity and the Bausch & Lomb LuxSmart Crystal, on the optical bench, using OptiSpheric IOL PRO2 (Trioptics, Germany) in order to assess the optical quality according to ISO 11979 with ISO-2 Cornea. IOLs (power 22.0 D) were evaluated regarding modulation transfer function (MTF) at 50 lp/mm and Strehl ratio (SR) using a 3.0-mm and a 4.5-mm aperture. In addition, wavefront measurements were obtained using WaveMaster® IOL 2 device (Trioptics, Germany), and USAF targets were analyzed.</p><p><strong>Results: </strong>Centered: the MTF (mean) at 50 lp/mm (AcrySof IQ Vivity/LuxSmart Crystal) with 3.0 mm aperture was 0.250/0.257 and with 4.5 mm aperture 0.202/0.243. The SR (mean) with 3.0 mm aperture was 0.261/0.355 and with 4.5 mm aperture 0.176/0.206. Decentered by 1 mm: the MTF (mean) at 50 lp/mm (AcrySof IQ Vivity/LuxSmart Crystal) with 3.0 mm aperture was 0.266/0.247 and with 4.5 mm aperture 0.126/0.215. The SR (mean) with 3.0 mm aperture was 0.272/0.234 and with 4.5 mm aperture 0.133/0.183. Tilted by 5 degree: the MTF (mean) at 50 lp/mm (AcrySof IQ Vivity/LuxSmart Crystal) with 3.0 mm aperture was 0.221/0.360 and with 4.5 mm aperture 0.214/0.229. The SR (mean) with 3.0 mm aperture was 0.232/0.428 and with 4.5 mm aperture 0.225/0.229. The simulated visual function using USAF test targets showed corresponding qualitative results. Wavefront measurements proved a complex optical design. Higher order aberrations in the central part of the optics were modulated up to the 10th order to enhance the range of functional vision to near distance, leaving the peripheral parts of the optics aberration free or as aberration correcting.</p><p><strong>Conclusion: </strong>The diversity of EDOF IOLs, their optics, and their respective impact on the vision quality must be understood in order to select the appropriate IOL in each individual case. This analysis of new, innovative IOL optics based on increased negative spherical aberration may help the ophthalmic surgeon to select the IOL which meets the individual requirements of the patient for best postoperative outcomes. It seems that there is no perfect IOL that is equally suitable for all patients, but the right choice is an individual, customized approach dealing with patients' expectations.</p>","PeriodicalId":9075,"journal":{"name":"Biomedicine Hub","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/88/05/bmh-0006-0077.PMC8613612.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39847957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
期刊
Biomedicine Hub
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1